Premium
Thrombopoietin activates the growth of megakaryoblasts in patients withchronic myeloproliferative disorders and myelodysplastic syndrome
Author(s) -
Hashimoto Shigeo,
Toba Ken,
Fuse Ichiro,
Watanabe Kenichi,
Takahashi Hidenobu,
Abe Takashi,
Yano Toshio,
Koike Tadashi,
Takahashi Masuhiro,
Aizawa Yosifusa
Publication year - 2000
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1034/j.1600-0609.2000.90001.x
Subject(s) - thrombopoietin , myeloproliferative disorders , myelofibrosis , acute megakaryoblastic leukemia , leukemia , cancer research , immunology , cell growth , medicine , myelodysplastic syndromes , acute leukemia , cell culture , progenitor cell , biology , haematopoiesis , stem cell , bone marrow , microbiology and biotechnology , genetics
The effects of thrombopoietin (TPO) on cell proliferation and differentiation, and the relation between these effects and the expression of c‐mpl on leukemia cells were studied in seven acute myelogeneous leukemia cell lines and seven myelogeneous blast cell preparations from patients with chronic myeloproliferative disorders (CMPDs) and myelodysplastic syndrome (MDS). Among the leukemia cells, five preparations of megakaryoblastic leukemia cells from patients and one megakaryoblastic cell line, CMK 11.5, proliferated in response to TPO in vitro . CMK 11.5 and the blastic cells from one patient diagnosed with MDS with myelofibrosis differentiated with increasing expression of CD41a in response to TPO. However, TPO had no effect on the cells lacking megakaryocytic characteristics. Some patients with CMPD and MDS develop acute transformation with blasts demonstrating megakaryocytic features, and some of these cells show growth in response to TPO. Therefore, in vivo administration of TPO should be considered carefully for patients with CMPD or MDS, since TPO may induce leukemic cell proliferation.